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Coronary angioplasty has gained wide aeceptancc as the 
proecdttre oi choice in many patients aith coronary artery 
disease Gtce its first introduction in I977 (1). Inttially 
restricted to patients with single vessel disease and stable 
angina. its use has been expanded to unstable angina. acute 
myocardisl infarction and multivessel coron~y artciy Jlr- 
ease Despite impmvementr in cquipmcnt nn~! ircnmque. 
acute reocclusion alter succcssf~l Lgiopla5ty occur\ m 
approximately 5% of palientr and Me re\tenoG\ Igcilerall) 
in.53 month& the most important problem after coronar) 
angioplasty. occurs in 25% to :iR of patients. We reccmly 
reviewed (1) the mechimiaas of acute wxluion and rc~tcnu- 
sis after angioplarty, and the currenity available pharmuco- 
logic approaches for their prevention. In thir report. me 
summarize our current understanding of the process of 
poangioplasty occlusion and resteno\i\. with \p+cial atten- 
tion to the contributory role of olateletr. thrombtn and 
thrombosis. orgaoizUion and incor&xaion of the thrombw 
and subsequent intimill hyperptwia. 
proliferation: and Jl the rote of currem pharmacologic rhcr- 
apy and powble future approachcr. 
Mechanisms of Dilalion of Stenotie Lesions 
htwhanisms. Experimenta! and clinical observations 131 
wgge\t that four mechanisms may be involved in succesrful 
angiopbw First. balloon inflation results in tears. fractures 
ad crack\ in the Qmotic plaqile. entargmg the channel 
ihmugh which blood is able to Row and improving ve-.set 
patmcy. Secunu. because plaque tears at the point of least 
re\~.mce. dissection rhrough the intima into the media 
cawes enliwgrment of the vessel lumen. With further bal- 
luon expansion. the media and adventitia of the artery may 
stretch to conform with the outer diameter of the inflated 
balloon. A thtrd mechanism by which bslloa angioplasty 
may \rorh i) through redibtributmn and compression of the 
pkique. nprcially plaque composed mainly of tbrombotic 
dcpuril>. fm&. depending on the degree ofeccentricity of 
the plequc and its composition. balloon i&lion may rewlt 
in di*tenGon or stretching of only the disease-free arc of the 
normid vc\w4 wll and produce little or no damage to the 
plaque itvlf. Although an initial increment in luminal diam- 
eter occurs. 11 may he to>1 within hours. days or seeks after 
the ddatlon as a result of gradual rclaxadon of the over- 
\Irexhed segment tre,titution of tone or elastic recoil). 
Recent observation\ IJI derived from microscopic eumina- 
lion of athcrcctomy specimens suggest that this mechanism 
m;by occur in up to !S% ofangioplasty procedures claartfied 
a> succc4ui bawd on the milial ang!ognm. Restenobis 
occurring in this fttshion entails a lack of initial plaque injury 
and scrvcs to highlight the central paradox of coronary 
angioplasty. For the procedure to be successful. deep vas- 
cular injury is required: however. the natural biologic re- 
sponses to such injury may result in acute reocclusion or 
restenosis. 
SprriJit 1111~. rl~rlcno.\i.t (‘,I,, he mll,sidtwd I, r,lerhnItbm 
of wxrrlor “kwlin~” cwd “r~~nodelin~” rkor rcrir1r.t pOnt 
ifljrlv 10 the nrrog o~rdprobrrhl~ owurs I0 10ntc &gree irr u/l 
(uses. Support for this concept derives from a recent serial 
angiographic study by Bcatt et al. 15). in which virtually all 
patients demonstrated deterioration of the mean minimal 
luminal diameter at 90 and I20 day angiographic follow-up 
study. even in those in whom clinical or angiognphic criteria 
for restenais were not met. Finding new approaches to 
limiting the thrombotic and fibroproliferative t~sponse to 
balloon-induced v~sculsr injury will be a formidable task for 
the basic saentist. 
Pathologic and Clinical Correlates in Acute 
Occlusion and Chronic Restenosis (Fig. 1) 
ACUIP Occlrrsion 
Angioseopic observations. Data derived from angioscopic 
observation!, as well as pathologic atdies of patients who 
died within hours to several da), :?-I successful coronary 
angioplnaty have provided insights into the mechanism of 
acute occlusion after coronary angioplasty. Percutaneous 
coronary angioscopy provides direct visualization of the 
immediate morphologic changes in coronary arteries in- 
duced by balloon angioplasty. Uchida et al. 16) recently 
reponed that major intiinal disruptions such as plaque rup- 
ture. intimal dissection. mural thrombosis and deep longitu- 
dinal clefts along the atheroma are commonly found imme- 
diately after coronary angioplasty. Mizuno et al. (7) also 
observed intimal Raps. imimal splitting. mural thrombosis 
and endothelial he&m’rhage in.the &j&y of patients 
studied. 
Autopsy studies. Such studies in patients who died within 
hours to a few days after coronary angioplasty have sug- 
gested similar morphologic pat!erns. Kohchi et al. (8) de- 
scribed a jagged lacerated intimal surface. with disruption 
and intimal Raps. focal mutal thrombi and fibrin deposits in 
three patients who died within 2 days after coronary angia- 
plasty. Ueda et al. (9) also found that plaque rupture with 
intimal flaps and fresh thrombi were universal findings in the 
cases stlrdied within 3 days after coronary tmgiaplasty. 
Similar morphologic descriptions have been reported by 
other investigators (10-17). 
Mechanisms. ACLIP nrclrrrim (11 fhe on~ioplmly sire fhns 
nppmrs to ix relined 10 one of seseral mechanisms. I) A 
large intimal Rap created by extensive itttimal-medial dissec- 
tion and usually associated with abundant thrombur proba- 
bly accoums for about 50% of the cases of acute occlusion. 
In the National Heart. Lung. and Blood Institute Registry 
118). about 5% of patients had evidence of m&r vessel 
dissection. resulting in acute coronary occlusion in 50% of 
cases. 2) Early occlusion that is predominantly thrombotic is 
particularly comtnon in cases where mural thrombi were 
present before angioplasty. Recent evidence from our l&w- 
ratory (19) has shown that the suriace of a thrombua pro- 
vides a potent stimulus for further deposition of platelets and 
fibrin. Mechanical disruption of such thrombus already 
present in a ruptured athemmatous plaque. coupled with the 
further thrombolic stimulus of angioplarty. leads to a very 
high incidence of acute closure after angioplasty in acute 
coronary syndromes. as htgh as 10% to 13% (20). In other 
cases. early tbrombotic cloture may occur when vascular 
trauma. not necessarily severe. is associated with significant 
residual stenosis. Residual stenosis results in rheologie dis- 
turbances causing elevated local shear stresses. which pro- 
mote platelet activation and deposition and thromhus forma- 
tion in the affected area (211. 3) Acute closure may also be 
associated with vasaspasm or early relaxation of an over. 
stretched disease-free s gment of the vessel wall (22). 4) An 
additional contributing mechanism to acute occlusion is 
subintimal hemorrhage that extends deep into the media. 
with pathophysiology similar to that of major dissection (3). 
This has been reported in cases where thrombolytic agents 
were administered before angioplasty. 
Pathophysiologie mechanisms. The most common mech- 
anism of postangioplasty restenosis involves the devclop- 
ment of tibrwellular intimal hyperplasia. with smooth mus- 
cle cell proliferation beginning witbir. 24 to 48 b after 
vascular injury (2.23). Although the pathophysiologic mech- 
anisms regulating this libroprolifcrati~e response are still 
unclear. rxperimen~al and pathologic studies have allowed 
us to observe the sequence of wents leadmg to restenosis 
and :o gain some insights inio the pathophysiologlc mecha- 
nkms. 
In rhr pig carmid me-p ong;vplu~i! mnll. balloon 
injury results in complete endothclial denudation wi!h vary- 
ing degrees of medial injury G!). In areas where balloon 
trauma resulted in a medial tear. marked plare!ci depo3itiun 
and macroscopic thrombosis occurred in most cases despite 
the use of hiih dose systemic heparin. In areas with more 
superficial injury lintact internal elastic lamina). platelet 
adhesion began to occur immediately and cominued until the 
entire denuded endathelial surface was carpeted with a 
single or double layer of platelets. Several hour? lafer. 
moderate numbers of leukocytes were also shown to adherc. 
At 24 h. there was evidence of necrosis of medial smooth 
muscle cells and significant numbers of platelets remained 
attached on the deeply damaged swfacc. Over the next 4 to 
5 days, a IO-fold reduction in deposlted platelets coincided 
with panic! endothelial regrowth. which was essentially 
complete by 7 days. At this time. platelet depositwn on wear 
of more superficial injury was practically undeteclahle. but 
in deeply injured arteries, mural thrombi commonly per- 
sisted with evidence of orranirat;at and incomoratirm in!o 
the vascular wall. resolti~g in some cases in.a significant 
stenotic lesion at 60 days. Within 7 days of injury in this 
model. patchy vascular smooth muscle proliferation could 
be noted by light microcopy. increa+np in ihicknos and 
uniformity over the nexl week. 
By the we ofbromodeoxgwidioe labeling. it ha5 recently 
been shown (251 that 16% to 20% of medial smooth muscle 
cells begin to proliferate within 24 to 48 h of balloon 
angioplasty. confirming data derived from other models of 
vascular injury. In the rat model (26). about 33% of medial 
smooth muscle cells began to proliferate shortly afier has- 
cular iojury. reaching a maximum at 48 h. After pdifcratinl: 
in the media, smooth muscle cells migrate to the intima at 
around 4days. at which time some undergo further cycles of 
cell proliferation. In these models. although the cycle of 
medial proliferation. chemotaxis and intimal proliferation 
had occurred maximally by I week. progressive inlimal 
thickening occurred for up to tt week, as a rc~~lt of the 
ongoing synthesis of connective tissue matrix and cellular 
hypatrophy. Overall. there models demonwate that there 
ii g striking correlation between the dsgrrre of endothelial 
denudation and medial injury and the extent of myointimill 
thickening. 
Autotw studies. Such studies in patients who died sew 
eral da&lo months after successful coronary angioplarty 
have revealed Q similar xquence of events leading 10 w- 
stenosis. Kohchi et al. (8) analyzed 20 coromw artery 
segments in nine patients who died at various times tbctucen 
days 2 and 140) after angioplarty. Morphologic changes in 
corotwy arteries 2 days after angioplesty included ruptured 
athematatoub plaques coated with layers of platelets. fibrin 
aod mural thrombi. Pathologtc feaure\ m coronary drterier 
I2 days after angioplarty included orgamzed thromhi and 
cellular proliferation witt:in 3 ionnective tissue matrix. In 
con!rrst. morpholoeic :ladmgs in coronary arteries I40 days 
after halloon mjilry have been predominantly those of 
pmoorh muxle cellr intcrzpcrsed within a dense connective 
lirwe woma. Other investigators P-17) atso describsd a 
krxilar sequence of path&@ event-, from sewr.d days to 3 
months after halloon angioplasty: plaque disruption wilh 
platelet deposition and thrombus formation followed by 
organization of thrombi. with development of an overlying 
fibrow cap. smooth muscle cell migration and probferatior.. 
all leading to intimal thickening and vasc?llar occlusion. As 
noted m the exprimentel eulel. pthologic studies con- 
firmed tha: ,mooth muscle cells bean to migrate to the si:e 
of injury as early as 6 days after batloon angioplasty. After 
migration. smooth muscle cells assume a synthetic pheno- 
type and presumably are responsible for subsequent connec- 
tive true synthesis. At the later Sra@ lI?lJ days). these 
smooth muscle cells reven back to the contrxtile pheno- 
type. 
Atberectom) studks. Recently. arherecromy has pro- 
vided an opportunity to studv atherosclerotic ssue removed 
from the coronary and peripheral arteries of living patients 
and I\ helpmg us to lain insight into the mechanisms of 
restenosis. In a recent study. Johnson et al. (41 described the 
histopatholoatc findings in 48 restenotic lesions excised from 
peri(;heral a&rieb by-atherectomy. Intimal hyperplasia wa 
found in the majority of cases. Thmmbotic material WBL 
found in 6E to 70% of cases to 3ome degree and lhrombi 
were large and in various stages of organization in 33% of 
restenotic lesions after angioplasty. In about 25% of cares. 
only atherorclerolic plaque was seen. su&wting that elastic 
recoil wa the mechanism of restenosis in these Casey. 
The pathophysiologic proeesscs leading to acute occlu- 
sion after coronary angioplasty are mainly related to either 
predominantly thrombotic mechanisms or major plaque dis- 
wtion with intimal Rapsand superimposed thrombosis. The 
pathophyriologic event) leading to chronic restenosis in- 
voive vascular injury. platelet deposition and thrombosis. 
organization and incorporation of thrombi and subsequent 
smooth muscle cell proliferation and connective tissue nyn- 
these\. The biochemical signals regulating the restenotic 
process in viva are complex and multtfactorid. However. 
substantial data suppon the concept that whenever there is a 
mural thrombus that remains unlysed by natural means. 
there is a fibrotic and pmliferaiive response in the vessel 
wall. Thlc concept has been stipponed in the case of rpon- 
tuxou atherosclerosis by pathologic observations of 
thromhi in various stages of organization being inccrporated 
into atherosclerotic plaque and by immunohistochemical 
recognition of fibrin and its related products within athero- 
sclemtic plaque (27.28). 
In the preceding section. we reviewed some of the 
expenmen~n!, angioscopic and pathologic evidence esrah- 
lhrhing a link between early thrombosis after anginplasty and 
incorporation of thrombi into the restenotic lesion. In the 
next section. we review some ofthe biologic determinants of 
thrombosis after vaxula injury and subsequent smooth 
mtiJcle cell proliferation. establishing a mechanistic link 
between the& pwcesses. 
Biologic Determinants of Thrombosis and 
Smooth Muscle Cell Proliferation After 
Vascular Injury 
Biologic Delrnninunrs of Tltrombosis 
Experimental mod& of vascular injury have suggested 
that the degree of thrombus formation and pers~rlence of 
such thrombi (Ihat ii. their ability to resist the eodogenous 
inhibitors of thrombosis and tihrisdytic systems) depend on 
the depth or exient of the vascular injury. as well as 
hemorheologic factors such as the distribudon of shear 
stresses around the injured segment. 
Role of vascular injury. The degree of vascular injury 
determines the extenl of exposure as well es Ihe types of 
thrombogcnic substrates in the underlying vessel wall (that 
is, collagen and tissue faciors) and thus principally deter- 
miner rhe aggreswene~ of the thrombotic response. On the 
basis of experimental data .,I( the dynamics of platelet 
deposition in vascular injury using our cnmwxporeal pafu- 
sion system. we previously described 121 a pathologic clas- 
sification of vascular injury (Fig. 21: In (vpc I wwulor injury, 
functional allenlion of endothelial cells occurs without 
significant ultra%tructural changes. as found in hypercholes- 
terolemic models of atherosclerosis. In such cases. no sig- 
niLant platelet deposition or thrombosis is seen. 111 rypr II 
vuscrdor PIjury. there is endothelial denudation with ruper- 
ficlal intimal damage. but the internal elastic lamina and 
media remain intact. When type II injury is induced, B 
monolayer of platelets carpets the injured area with a vari- 
able amount ai thrombosis. In type Ill voscrdor injury. deep 
intimal and medial damage occurs with exposure of highly 
thrombogenic components of the medial layer. particularly 
fihrillar collagen and tissue thromhoplastins, resulting in 
marked platelet aggregation and mural thrombosis. This is 
the most predominant lype ai injury induced with balloon 
angioplasty. 
Role OP hemodynsmic shear stress. The degree of platelet 
deposition and thrombosis is dewmined not only by the 
iepw of in;ury. but also by the transport mechanisms of 
platelets to the injured area (21). P!e.telet transport is deler- 
mined partly by the wall shear rate, a measure of the 
difference in blood velocity between the cenler of the vessel 
and along the arterial wall. To investiapte the dynamics of 
platelet deposition and thrombus formation after vasadar 
injury and study the influence of shear stress, a computer- 
assisted nuclear scinligraphic method was developed (29) 
using an extracorporeal perfusion chamber in which different 
vessei wall substrates can be exposed to flowing bled at 
different shear rates. When lhis model was used. exposure ai 
deendothelialized vessel wall (mimicking supalicial or type 
II vascular injury) to blood at low shear rales induced 
adhesion of only a single layer of plalelets. At higher wal; 
shear rates, platelet deposition was greater and lhrombus 
formation occurred at IO 10 20 min: however. the thrombi 
were labile and fransienl(30). Exposure of tibrillar collagen 
to blood (mimicking deep or type III vascular injury) pro- 
duced platelet deposition that was two limes greater fhan 
that before such exposure. and thrombi that formed were 
well anchored and permanent. The number of platelets 
deposited increased significantly with an increased wall 
shear rate. as may occur in viva at a sieniticant residual 
stenosis. Analysis-of the axial distribution-of platelet depo- 
sition indictded that Ihe ~DEX of the stenosis. not the distal 
zone of flow recirculation~ was the segment ai the greatest 
platelet accumulation (31). 
Thus. in the experimewd laboratory. the combination 
ol deep vascular injury and elevated shear rales results in 
an increased stimulus for platelet deposition and thrombo- 
sis. This situadun has a clinical corollary in the observation 
that severe residcal stenosis atIer coronary thrombolysis 
strongly predicts rethrombosls (32.33). In rhe comext of 
coronary angioplas~y, balioor! htlation invariably rwdh in 
severe type 111 vawdar injury. If the mitA hemodynemtc 
rcwl, is suboptima and a rigniiicanr residual Devon remain. 
plaklet dcposilion IS augmented because of the presence of 
elevated wail shear r&es al the ,icc of Ihe lesion. The more 
imcnze platelet-vessel wal! imeric,,on increases pIalec- 
mediated intimal hyperp&.. This scenario ia in accord wilh 
the clinical obser\?!;on tha, a postangioplarty reGdual \ce- 
nosis ~-30% or a lranstenolic eradicnt ~-15 mm HP is 
predictive of restenosis (34). Ho&r. this does not co&a- 
diet the Bet that sexre type III vascular injury wirhou, 
angiognpbi. ewdcnce of reridual stenosis can by ilself lead 
to thrombotic occlusion and. in some case-~ also ,o throm. 
bus-mediated reslenosis. 
Biologic Determinants of Smooth Muscle 
Cell Proliferation 
The complex and m?lhifacrorial procerses rcgulaling 
smooth muscle cell migrdtion and proliferation in viva are 
incompletely understocd. Expamcntal vidcencc sogges~s a 
role for vascular injury, o>sillatory shear stress and ,hrom- 
bin in the proliferative proces afier vascular injury. 
Role of vnreular Injury. Vascular injury may influence 
smooth muscle cell prolifera,ion and connective tissue wn- 
thesis by the direct elTects of trauma on cellb of the vaxular 
wall and by indirectly creating a milieu for the interxlion of 
thrombus or cloltiq materml with the injured vessel I?). 
Direcr e.ij”wrs of vusrrdor mrunu~. Vascclar injury may 
promote smooth muscle cell proliferation by anragonizmg 
the growzh-inhibit”? processes of the undamaged &cry 
we!!. In the res, s,me. vascular rmooth muscle cells prolif- 
erase at very low levels: thus. <I% of medial smooth mucle 
cells we lob&d with hromodemyuridine in normill anery 
segments compared with 40% ,o 50% in damaged wgmems 
after balloon abrasion l?j). h growth-inhibirory e&l of 
sonic ex,rac,s was firs, demonsirated >50 yran ago USI. 
More recemly (36.371. the demonarrmion lha, exogenour 
heparin inhibits smooth muzclc cell prolifernion in responre 
to endothelial denudation. coupled with evidence lhat end@ 
thelial cells svnrherire srowh-inhibitorv heoarin-like clv- 
cosaminoglycans. led to ,he hypo,he+ I381 that a fonc,~on~ 
ally inmct endothclium helps maimmn rhe mcdra m a 
qmescen, smle. IIL~.x, evidence suppor,~ this concepi. 
When ,mall arear ofthe wsculilr widl ilre deendo,heli:dired. 
rapid regenerelion occur\ w!h minimal mfimal hypcrplaua 
however. when more fndolhelium i\ removed. inlimA hy- 
perplasi;~ isgreater and occur\ msumally in the areu where 
endothellal regeneration 8occurrcd l&t (39.40). Smooth mom- 
cle cells ,dso produce a growth-inhibilory hcpar.m wlfme 
and may help ,o maimion ,hemrches in a nonproliferming 
smte and comrxlilr phe.lo,ype 01 I. Balloon angioplasry 
may reverse this gruvthmhibitory lone by removing Ihe 
endothcliom. ad plmelct~ that adhere may relexe anlihcp- 
arin fx,orr wch as platelet factor 4 and heparitinares ,hl 
rcveric ,he c@ecls of hcparrm sulfates synthesized by 
smrolh mwclc cells (42). In addition to these effects. vas- 
cular trnoma may resuh in the release of mitogens such as 
plalelcr-derived gromh Bclor an+ those directly from dam- 
aged endo,he!ral and smooth muscle cell5 143-451. Ballwn 
diQen,ion titszlf has been rhown IO produce medlal smooth 
muxlc cell prolifcerarlon. bu, without mignrion of cells into 
,he intima (46.47) 
Plarrkr-wrsrl wall inrrrrictio,r. As discoved in vhe pre- 
vious \ec,iom. plateleis rapidly depos,, on Ihe injured var- 
cular wall in numbers that depend on the depth and extent of 
m~ury and hemorheologic condittons 12231. Shortly alter 
platelets become adhercm. they release nearly dl the con- 
IFIN’ of their alpha gmnules. including pZa,ele,-derived 
gro’.,h fxror and other mitogenic faclors fepidcnnal &owh 
frclor and beta-a-transforming gmwth factor) !%). It is as- 
somed rhat all there factors penetrate rhe vascular wall. as 
observed directly in the caze of piatele, factor 4 (an anti. 
heporm substance contlined in ,he alpha granules that has 
been dewted 1491 in the anerial imima and media within 
30 min of plalclcl adhesion). The combination nfendo:h&i 
dam&g? 3nd ~cireiion o, heparin-neutralizing factors by 
plalelet~ may release smoah musck cells from growth 
mhibnion and render [hem suncsp,ible 10 slimulation by 
plarelc,.&ived growth fac,or. Once the latter is bound io 11s 
receptor on Ihe smooth mwle cell. the cell is able to rmer 
the cell cycle: progression into the active phase of rephca- 
lion may depend on the >yn,hoir of mxdin-like growth 
I;rctor (somatomcdin Cl bv rhc smoah muccle cell IMSII. 
The rehwc importance bf platelet-derived grotilh factor 
compared with the epidermal grow,h facror and beta- 
tmwforming grouth bctor is unknown. but cxperimenmlly 
ij?l rhwc milogens exen a synergistic eITect on cclhdar 
prolifcm,ion. Smoolh muscle cell proiiferation commues 
beyond the phase ofplatkc dcpuskion. suggeeaingthat once 
m,,,a,cd. Ihe process may be perpetumed by other meant. 
Recmtlv. i, was shown rhs, activated smooth muscle cells 
from human mheromas are able to secre,e mitogenic pro- 
iem\ wembling platele,.derivedgrowthfactor. Walkercr rd. 
1451 demonclrdted [ha, there is a IO-fold increase in the 
producuon of these proteins by smooth muscle cells isolated 
from the arterml imima ? wets after balloon injury com- 
pared wilh cells derived from noninjured media. ti;mg the 
\enG,iw ,echnique ?f m SIIU hybridizalion. Wilcox et al. (53) 
Jcmon,,ra,ed the presence of p!meler-derived growrb faclor 
mRNA Iccrdizcd ,o the indma. bm not to the media of human 
carotid plaques remoied by endarterectomy. 
These data sugger, lha, once rmooth muscle cells are 
activated and migmte IO rhc intima. their continuing aciiva- 
lion may be self-perpemated. The inilial activation IS very 
likely due to the plstelet-vessel wall intemction. Evidence 
for ,his K derived from a slody by Friedman et al. 154). in 
which thrombocytopenic nbbi,s subject to balloon anerial 
abmsion exhibited rignificanrly less infimal thickening than 
comrol animals with normal platelci coun1s. More recenlly. 
inuma. but not the initial cycle of medial proliferation. 
Ahhoueh wecul:~tivc. I( ic noGhle that proliferation within . 
the mcd,u may hc ~ggercd by other ~rdluencea Isuch as 
balloon o~cnwnl. whereas mi$ralion may require platelet. 
denwd growlh fuctor. ahich i\ known to have chemotaclic 
OS well a\ m!togenic activities. Finally. us a rcapoore 10 
vwoIar anjury and mflammation. tlggregaled mononuclear 
lymphocytes may pl.ty a role in intimal proliferation wilh the 
releae of their cytohincr. \uch n% Wmor necroC factor. 
interleukir#s and beta-transforming grow!h fxtor. 
Role 01 hemodynamic shear stress. The imporlance of 
ahnormal duid hemodynamics in the regulal~on of smoolh 
muscle cell gruwh is illuwated by the experimental and 
pathologic obwvation that in the course of spontaneous 
a!heroxlerow. inlimal hyperplaw is most prominent at 
bifurcation>. gcneraliy 10. ;ha; half of the chcumfcrcncc 
oonosile IO the Row divider widl (SS.Sbl. Thus. in mosl 
model, of rpontaneoos and acccleretcd alherosclerosis. 
moat eccentric intimal thickenings and advanced fibmus 
athcromalou, plaques are restricted lo bifurcations of the 
major epicardial coronary arteries I571 and the brachioceph- 
alit and carolid arteries 158.59L Although investigalorr agree 
that hemodynamic forces play a role in the regulation of 
smooth muscle cell growlh. there is some disagreement on 
the ninure of these force,. Al present. the consenw is that 
the aner wall. where inlimal hyperplaria is inirially most 
prominent. is a site of low and oscillalory shear stress. Both 
low and oscillatory rhear stress contribute to an increased 
Ruid residence time in the vascular conduit. which may 
resulr in the modification of and interference with Ihc func- 
tion and mctaholi~m of cndolhclial cells. In addition. plule- 
ICIS and monocy~es would be expected to have an increased 
probability of deposition or adhesion in such regions because 
ofthe increased residence time. Funhermore. assewnent of 
shear stress in human cadaver experiments @C-h!) has also 
provided strong evidence [h&l intimal proliferation tends to 
be mo\t prom&t in wgments of arteries with low wall 
shear rlress. The mechanism of Ihe “milwzenic” elTecl oi 
low and oscillslory ahear slress i> unclear: however. in vitro 
and in wvo studies (63.64) have suggested that low wdll 
shear mess may impair recovery of endothelial cell function 
afier denudation. Thi, effect may thus remove the anlipro- 
liferative elTec& of an irdacl endothelium. 
To apply these conceals 10 the clinical selting. we previ- 
ously suggested lhai ripnificam residual postangioplwy 
stenosis may be associ;i!ed with elevated wall sheer raes at 
the bne of the lesion and that the postslrnolic segmenl is 
raw&ted with Row separation and is an area of low or 
osallatory shear west. Thus. ahnormal hemorheology may 
alTecl the restenotic process in two ways. High shear stress 
at the site of the residual lesion may favor platelet deposition 
a~4 Induce thrombus formalmn, part~ularly anrr vascular . ,... 
b scwunory. WC have discussed the pathophysiologic 
processes of thrombosis and smooth muscle cell prolifera- 
tion after vawdar injury os related to coronary angioplasly. 
These IWO proccrscs are intimalely related and occur in a 
milieu created by vascular injury and the inleractions among 
various cc1IuInr components of Ihe blood and vascular wall. 
In the nexl section. we discuss the clinical experience in the 
m,ury. LOW ano oscumxy snear smsr I” me neignoonng .^ .” pnarnracomg~ prevenuon of reswnosls awr coronary an- 
segment\ dialal LO the residual lesion may favor intimal 
proliferalion. 
Role of thrombin. Pathologic studies and athcrectomy 
specimens have wgpested lhal the organization and incor- 
poration of thrombus into the atherosclerotic lesion play a 
significant role in the restenotic procesr. Emerging enpcri- 
max4 evidence I651 suggests that alpha-thrombm. which 
has a central bioregulalory function in hemostais and is 
generated at high concentration during blood clotting, may 
hsve an important role in !he regulaCon of smooth muscle 
ce!l responses to vascular trauma. During thrombosis. 
thrombin becomes liehlly bound to Ihe arterial extracellular 
matrix. where it r&&s actively thrombotic with a long 
half-life and protecled from Ihc inhibitory elfecls of anli- 
thrombin III. Incorporated in the extracelkdai matrix or into 
clots. it may be rclcased gradually in its active form during 
spontaneou, fibrin&is or during the stage of thromhus 
organizrdion (66). In this manner, thrombin and its derivative 
products may participate in post-lhromhotic vascular 
events. including Ihe later stages of the myoproliferative 
procers. while plalelel-derived mitogens arc released only 
durmg platelet degranulation at the onset of thrombosis. 
Thus. plalelet-derived products may predominantly play an 
inidal rather than a sustained role in smooth muscle cell 
proliferation. Thrombin. however. may be chronically gen- 
erated at sites of vawlar injury by release during thrombal- 
ysis and by continued aclivation ofthe coagulation palhways 
in the presence of dysfunctional endothelium. Thus. throm- 
bin miy be import&l in the long-term alterations of smooth 
muxle cell function after vascular injury and platele! depo- 
&ion 1671. 
Ibmmhb bt twrioas forms has heen demonrrruted 168 to 
huw niiro~enic ncrh,iiy /or fibroblasrs und orber cells. 
Aloha-lhrombin alimulales several inWa.cellular events in 
co&n wilh other growth factors, including phosphoinasi- 
lide hydrolysis. increased intracellular calcium concentra- 
Lion and sodium influx in platele(s and fibroblasts. Recent 
work by Huanp et 81. (699) has demonstrated that alpha- 
lhrombin is mitogenic for smooth muscle cells irolaled from 
the neonslal rat heart. Berk et al. (67) also showed alpha- 
thromhin 10 he a pcdent activator of multiple growth-related 
signals in smooth muscle cells. including Ihe expression of 
the c-51s oncopne. which may be relared 10 !he significant 
increase in protein synthesis. Thrombin is also known to 
mediule vaculnr smooth muscle hypertrophy in vitro 167). 
and further work is needed to establish Ihe relevance of this 
finding to the in vivu process of int;mal thickening n&r 
vusculiw injury. 
gioplaxty and the emergmg ,herapcutic aategie\ ha& on 
our current undenlandirg of the pil,hophyGologic mccha- 
nism. 
Pharmacologic Prevention of Restenosis 
(Table 1) 
Pasr Experience 
Antithrombotietherapy Given the :mpatance of platele, 
deposition and mural thrombosis in <he pathogene\ir of 
postangioplasry restenaris. I! appcarec logical 1ha1 Ihk might 
be prevented wi,h antithrorohotic Iherlpy. In ,he cxpenmm- 
tal model. conventional antithrombotic therapy lim,t> bu, 
does not prevent the lhrombotic responw to deep VPSCUIP~ 
injury. However. in the clinical comcx,. amithrombouc 
therapy significantly reduces ,he incidence of;~cu,e ischemic 
complicalions after angioplasty without affectin% rerteno% 
rates. No beneficial et%: was shown with the use 01 atpirm 
in five placebo.controlled rdndomiLed trials 170-751 in duke\ 
rang& from 80 to I.500 mgfday. wah or withour the u\e of 
dipyridamole. Ticlopidinc. anulher platebe, mhlbnar. WI 
similarly ineffective in a dose of 250 me twice daily com- 
pared with aspirin and dnpyridamole or placebo 1751. hu! 
showed a beneficial trend in preliminary rc~lt~ from a wn~ll 
trial 1761 when combined with nicorandil. Preliminarv rewh~ 
with ciprostene 177). a prortacyclin analog. showi a Irend 
toward less restenosn in a s,udy involving 31 I patient>. but 
overall results with similar agems xc inconclwive 177.78). 
Heparin irlrpqnotri~ es& us a,, wnn.onp,drrm I0 pnwnt 
I(CI(IC flmro,,,ho~ic r~~f<n<wu ,&r WQ&>~/~I.U~. However. 
despite evidence that heprin may inhibi, smooth cell prolii. 
eration in vitro. its use liter aneioolasty has been in.tde- 
quately tested. In one stbdy 1791 involving 416 patients. high 
dose intrdvenouz hcparin adninistered for only IX 10 24 II 
after angioplasty wils no better than placebo. However. no 
s,udy has ye, ,e%ed the use of heparin admini\,ercd for 
Ion& period> after angiupla~ty. Wi,h regard 10 oral antico- 
agulants, ,hc adminiclrstion of warGn or aspirin at a dare 
of 325 mglday resulted in wmlar ~t!*tenoG rates in a 
nonplacebo-controlli trial (741. 
Omqa-3 fatty acids. Thw are found in sal,ea,er h\h 
and ha~c placlc, inhdx,oT and am-inflammalo~ prapenies 
<,< a rc,ut, of ,he,r etTec,s on platelet and leukwytc mem- 
brane phapholipidr. Adm,mwra,ion of omce-3 fatly acids 
ha\ been aw&ted with improved cndothelial-dependent 
r&na,wn in human subjects rith atherosclerosis 1801. Re- 
ten, rwdence ,811 s?ggcus an antiprobfemlive action due 10 
mhihitwn of platelet-dewed groath farlor %yn,he\i, in 
cul,ured endothelial cell% Experimatal evidence IK?) rug- 
gn,\ lha, omega-3 My acid, may inhibi, in,imal h>perplnsia 
induced hy Moon injury and hypcrbpidemm However. fwc 
randumircd clinical ,rial* 1X.3-87) of omega-3 faltv ncidr in 
pos,anp~~pta~,y rcr,enos~s hwe yielded conflicling and can- 
,ro~crwd rcwhb. In one ,rkal. Dehmere, al. (83) randomized 
X? m+n !\t,h 103 coronary artery lesion> 10 receive 3.2 g of 
omc~+l fa,,y acidr or placebo in addition to aspirin and 
d,pyr,damolc. fhcrapy was begun I week before angiopldsty 
and continued for h month\. Compliance with therapy was 
;wewd hy determina,ion uf pla,clc, membrane fat,) acid 
campoaion: restenosk WI\ identified by repea, coronary 
angiography. This s,udy showed a significnn, rcduclion in 
re\,cno\i\ in ,he ,rca,men, group whether analyred per 
lc\iun 1365 versus 16%) or per patient (46% VCRUS IWI. 
The<e encouraging resuI,s wre no, corroborated in the two 
other placebo-controlled studies IR4.851 with angiogmphic 
folkxv-up study using doses 0, I .8 and 6 glday of omega-3 
L,ty acldx in neirher of ,hese srudies was ,hcnpg begun 
before angioplasly. Tbc only orher study (86) in which 
omera-3 h,,y acid ,henpy was hewn &fore angioplasty 
rep&d a decrease UI restenosis from 35% in control 
o&en,\ ,o 2% in oaients recewinr 4.5 e/day. but it was not 
placeho controlled and follow-up &alu&o~ was based on 
cbmcal symptoms and exercise test results m a stepwise 
fahion. In ye, analher study 187) with clinical follow-up 
dam resknosk occurred in 34% of palienrs receiving 3 g/day 
of omega-3 fatly acids V~~EUI 32% of patients in the control 
group: hwever. for unclear reasons. subgroup analysis 
\howed a hen&id effect III the gwup of patients with single 
vrsbel direasc. Gwn the variaiion in study design. the 
awlable d;itn m(1s, be interpreted with caulion. Because 
many orlhe biologic effects uf omega-3 fatty acids depend on 
their incorporation inlo cellular membranes. it is likely thal B 
loading period is required for maximal effectiveness. Fur- 
thermore, anpiognphic follow-up study is probably required 
to make an accurate assessment of restenosis. For example. 
in the study by Grigg e, al. 184). restenosis was angiograph- 
ically prewnt in only SI’S of patients with recurrent symp- 
toms and in only 55% of those with a positive exercise test. 
Whh thew con5idelalions in mind. we believe that the 
current data regarding the use of omega-3 fatly acids in 
angioplasty are inconclusive. but warrant further study. 
Corticosteroids. In autopsy studies, mownuclear lym- 
pbocytic infiltration has been noted at the site ofangioplasty. 
sugesting that inflammatory processes may play a role in 
restenosis. In the experimental model (88). corticosteroids 
have been shown to inhibit smoolh muscle cell proliferation 
after balloon-induced injury. However, in a large clinical 
trial 189) involving >9QO patients. high dose methylprednis- 
olone given as a I E bolus iniection before aneioplasty was no 
better‘than placebo in rehucing restenos~ r&s.. In two 
smaller studies l90.91). the use of oral steroids for 7 days 
aflcr angioplasty was similarly inelfective. 
Role of exercise testing and euronary dilators. Finally. an 
early (within 3 days after coronary angioplasly) positive 
exercise stress test has been shown (921 to predict resteno- 
sis. In this study (92). some patients with a positive wess 
test had a normalized exercise electrocardiographic re- 
sponse afler intravenous verapamil. suggesting vasospasrn 
as a cause of the abnormal stress response. Accordingly. 
coronary vasospasrn has been suggested to play a role in the 
rcsteimtic process. However. experimental and clinical stud- 
ies 193.94) have failed to demonstrate beneficial etTects of the 
calcium channel blockers diltiazem or nifedipine (93.94) or 
the aerotonin antagonist ketanserin (95) in decreasing the 
incidence of restenosis. It is important to realize that a 
positive slress test early after coronary angioplasty may 
entirely reflect the presence of mural thrombi which. al- 
though not visualized by coronary angiography. is a common 
finding in coronary angioscopic studies (6.7). In addition to 
obstructing euronary blood tlow. platelet thromhi may in- 
duce coronary vasospasm in the absence of functionally 
intact endothelial cells and thus account for the early posi- 
tivity of the stress test. Conversely. a positive stress test in 
patients several months after coronary angioplasly probably 
reflects the eventual process of librolic organization of 
thromhi and intimal hyperplasia. 
In view of the many studies just discussed, his clear that 
no currently available therapy has the potential to limit 
pnstangioplasty stenosis. Thus. there is a need to develop 
new therapeutic approaches to this problem. One strategy is 
to develop more palent antithrombotic agents. perhaps with 
the ability to inhibit the final pathways leading to platelet 
aggregation and release of growth iaclors. Altemrtively. it 
may be possible to develop drugs that inhibit the migration 
or proliferabon of the vawlar smooth muscle cell. In this 
section, we briefly describe some agents currently under 
investigation. 
Antithrombotic approach. Although we have emphasized 
the importance of mural thrombosis with a subsequent 
fihroproliferative response in the pathophysinlngy of re- 
stenosis. adhesion and aggregation of platelets to the YBSCU- 
lar wall with release of mitogens and chemoattractants for 
smooth muscle cells may be sufficient to initiate intimal 
hypetplasia. Perhaps conventional antirhromhotic ageats are 
ineffective in preventing restenosis because none are capable 
of inhibiting this process. Platelet adhesion depends on the 
interaction of platelet membrane alycoproteins (such as 
glycopro~ein l&b1 with adhesive ticr~molecules in the 
exposed subendothelium (such as van Willebmnd factor) 
IFig. 3). Approaches to prevent platelet adhesion with vari- 
ous agents are under invesligation. 
f/m&r oppreperbn depends on /hrw pafhwws lending 
IO pfyuaprorein Ilrrllllh ~.rposure. Several convenlianal an- 
tithrombotic agents inhibit only one of the earlier pathways 
of platelel aggregation. hut have not demonstrated complete 
efficacy. Currently. agents that are effective in blocking the 
final pathways lthat is, interactions between glycoproteins 
IlbRIla and van Willehrttd factor leading to platelet aggre- 
gation) are under intense investigation. Thus. monoclonal 
antibodies directed against glycoprotein llbillla h ve re- 
sulted in significant protection against thrombosis in the 
baboon vascular graft model (%) and experimental canine 
coronary angioplasty (97). In addition, similar anti&dies 
have been shown (98) to accelerate the rate of coronary 
thrombolysis induced by tissue plasminngen activator and 
prevent reocclusion in dogs. Recenlly (99). monoclonal 
antibodies directed against glycoprotein IlWIlla have been 
tested in humans .with unstable angina and demonstrated 
profound platelet inhibhion without acute toxicity. If etTec- 
;ive. the necesrary duration of therapy and feasibility of 
longer duration of therapy need preclinical investigation. 
with possible subsequent application to patienls after coro- 
nary angioplasty. An alternattve target for antibodies is the 
van Willchrand factor itself. In studies (Ml) using an extra- 
corporeal perfusion chamber. monoclonal antibodies di- 
rected against van Willebrand factor resulted in an 81% 
reduclion in platelet deposilion on deendathelialized bled 
vessel wall or type I collagen compared with a reduction of 
only 3% obtained with the use of aspirin. 
in view of the xipnjficance ofthrombin in fhrumhosis and 
probably in smomh muscle cell proliferation. riw use of 
sprrifc inhibirors of rhrombin opp~ars promising. The best 
studied of such ageents. recombinant hirudin. nigniticandy 
decreased platelet and fibrinogen deposition and abolished 
mural thrombus fonnalion in the pig carotid angiop!asty 
model (IO!.illZ). Synthetic peptide-inhibitors of thrombin 
have also shown (103.104) grealer efficacy than have con- 
ventional antithrombotic agents in vascular graft and carotid 
endatterectomy models. Although the monoclonal antibod- 
FIgwe 3. Schematic diagram of biochemical 
inteactions between platelet membrane recep- 
tors. vessel wall and adhesive macromole- 
cule~ during platelet adhesion and aggregation. 
VWF = van Willcbrand fac!or. Reprinwd from 
Stein et at. (107) wth permission. 
ics and anlithrombin drugs are clearly powerful antithrom- 
boric agents. their et%& on restenosis are slill unproved 
and their safety with regard to hemorrhagic side effects 
needs to be established. 
Aatiprdiferative approach. We have emphasized the im- 
9wamce of smooth muscle cell proliferation after vascular 
injury in the pathogen& of restenosis. The many ueps 
involved in this process may offer a target for pharmacologic 
intervention. As mentioned. heparin is known to exert an 
inhibitory effect on vascular smooth muscle. although lhe 
high doses required for such an effect present practical 
problems for clinical application. However. recent evidence 
(88) suggests that the antipmlifemrive etiectr rosy be related 
primarily to low molecular weight moieties. wilh little anti- 
coagulant activity. Thus. it may be possible to use fmction- 
ated low molecular weight heparin derivatives. with little 
risk of bleeding and this approach is currently being ioves- 
tigated. Other possible antiproliferative appmachcs include 
developing drags that inhibit the release or block the elTcca 
of plat&t~de&ed gmwth factor. The role ,f the ang otensin 
system in mediating myointimal thickening requires funher 
study. Although in vitro evidence suggests that angiotensin 
results in smooth muscle cell hypertrophy without an in- 
crease in cell number. cilazapril. an angiotensin-converting 
enzyme inhibitor. was recrndy shown (1051 to significantly 
decrease intimal thickening in the rat angioplasty model. It is 
likely that the development of a xife and elTcrtive sotipro- 
liferativc therapy will depend on an improved undersfandmg 
of the regulation of smooth muscle cell growth and the 
pathophysiology of vascular injury. 
almost NM times the dose thal might be used clinically f 103). 
Simtlarly. the are of a continoou4y high done of intnwnous 
heperin m rat, (36.37) to achieve il sxum concentnlion thpt 
xouid \igniiicantly suppress smwth muscle cell gtowh 
would prove to be impractical in !he clinical setting. Thus. 
techniquer are being develovd to achieve local infusion of 
therapeutic zIgems (antithrombotic or anliproliferative 
ageenw to the damaged vascular wall. This may provide a 
high local cooccrtwation of the drug and thus minimize 
systemic toxicity. Indeed. EMnan et al. II061 recently 
demonstrated the feasibility of a local coolrolled release 
rystem of heparin in inhibiting smooth muscle cell prolifer- 
ation after vascular injury. Such an approach may remove 
!he inherent problems of systemic administration of potent 
therapeutic ageots. Continued development of this type of 
therapeutic technique in the management of the restenotir 
process after coronary angioplasty is clearly indicated. In 
addition. because rcstenosis may be a continuous process of 
platelet deposition. thrombin generation. thrombus organi- 
zation and smooth muscle cell growth. a continuous infusion 
of therapeutic agents using a delivery system (wch as the 
dearadab!P %tent) may have significant clinical potcnt~al. 
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